in vitro Safety Pharmacology for Small Molecules

For those of you interested in drug development- we arranged this next online Meetup to discuss in vitro Safety Pharmacology for Small Molecules

TTarget-based safety assessments are now essential for prioritizing compounds and identifying candidates with desirable safety profiles in the early phases of drug discovery. in vitro safety pharmacology greatly contribute to structure-activity relationship (SAR) research efforts and thus increase the likelihood of clinical success.
As a result, in vitro binding and functional pharmacology assays regrouped in panels together with novel translationally relevant phenotypic approaches, now offer a competitive advantage to effectively and efficiently select the most promising preclinical candidates for effective drug discovery programs. Beside general safety, focused approaches (i.e. drug abuse, endocrine disruptors etc…) are also available.
In this presentation, Annie Otto-Bruc will highlight how Eurofins Discovery has developed, over the past decades, state-of-the-art in vitro off-the-shelf and custom solutions used by leading pharmaceutical and biotechnology companies, tailored to the needs of chemists and biologists involved in drug discovery and safety pharmacology.

About the speaker:

Dr. Annie Otto-Bruc holds a doctoral degree in Biology and Pharmacology from Nice-Sophia-Antipolis University, France and gained 10 years’ academic experience in pharmacology, molecular biology, protein-protein interaction, fluorescence measurements and enzymology both in France and USA. Since she joined Eurofins-Cerep, now Eurofins Discovery, in 2002 as a Drug Discovery Study Director and member of the Scientific Support team, she has been handling in vitro pharmacology studies for client drug discovery programs (HTS, Hit-to-Lead, Lead Optimization and Safety) with various types of assay content (binding, cellular functional, enzymatic assays or custom development). In close collaboration with our clients and Lab Operation Departments, she ensures the studies are conducted according the best practice. Recently she has been focusing on technical support for our KinaseProfiler™ assay platform.